A 48-year-old woman with ER-positive, HER2-negative, node-negative breast cancer has an Oncotype DX recurrence score of 18. According to the TAILORx trial findings, which management is most appropriate?

• A Chemotherapy followed by endocrine therapy
• B Chemotherapy alone without endocrine therapy
• C Neoadjuvant chemotherapy followed by surgery
• D Endocrine therapy alone without chemotherapy ✓

Explanation

The TAILORx trial demonstrated that patients with ER-positive, HER2-negative, node-negative breast cancer and an Oncotype DX recurrence score of 0–25 derive no benefit from adding chemotherapy to endocrine therapy. A score of 18 falls within the low-to-intermediate range where endocrine therapy alone is sufficient. Chemotherapy is reserved for scores of 26 or above in this population.

Reference: Bailey & Love's Short Practice of Surgery, 27th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.